Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2009 - 2026)

Vertex Pharmaceuticals has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $55.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 15.5% year-over-year to $55.9 million; the trailing twelve-month figure through Mar 2026 stood at $217.3 million (up 7.52% YoY), and the FY2025 full-year result was $209.8 million, up 1.25% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $55.9 million, roughly flat from $55.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $59.0 million in Q4 2023, with the low at $35.9 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $47.2 million, with a median of $48.4 million recorded in 2025.
• Year-over-year, Depreciation & Amortization (CF) surged 53.65% in 2023 and slipped 21.19% in 2024.
• Tracing VRTX's Depreciation & Amortization (CF) over 5 years: stood at $38.4 million in 2022, then surged by 53.65% to $59.0 million in 2023, then fell by 21.19% to $46.5 million in 2024, then gained by 19.78% to $55.7 million in 2025, then climbed by 0.36% to $55.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $55.9 million (Q1 2026), $55.7 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.

Peer Comparison